ProCE Banner Activity

MagnetisMM-1: Efficacy, Safety, and Tolerability of Subcutaneous Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma

Slideset Download
Conference Coverage
Subcutaneous elranatamab, a BCMA-/CD3-targeted bispecific antibody, had a manageable safety profile and encouraging activity in relapsed/refractory multiple myeloma as reported in the MagnetisMM-1 phase I trial.

Released: June 14, 2021

Expiration: June 13, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme